Analysts Set Lifecore Biomedical, Inc. (NASDAQ:LFCR) Price Target at $5.50

Lifecore Biomedical, Inc. (NASDAQ:LFCR) has received an average recommendation of “Hold” from the five brokerages that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and two have assigned a buy recommendation to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $5.50.

Several research firms have recently commented on LFCR. Weiss Ratings restated a “sell (d)” rating on shares of Lifecore Biomedical in a research report on Thursday, January 22nd. Barrington Research raised shares of Lifecore Biomedical from a “market perform” rating to an “outperform” rating and set a $5.50 target price for the company in a research note on Tuesday. Finally, Zacks Research upgraded shares of Lifecore Biomedical to a “hold” rating in a research report on Thursday, January 1st.

Hedge Funds Weigh In On Lifecore Biomedical

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Legion Partners Asset Management LLC increased its position in Lifecore Biomedical by 0.7% in the 3rd quarter. Legion Partners Asset Management LLC now owns 4,461,823 shares of the company’s stock valued at $32,839,000 after acquiring an additional 30,000 shares during the period. Greenhaven Road Investment Management L.P. boosted its position in Lifecore Biomedical by 2.2% during the 2nd quarter. Greenhaven Road Investment Management L.P. now owns 3,694,832 shares of the company’s stock worth $30,002,000 after acquiring an additional 78,686 shares during the period. Vanguard Group Inc. boosted its position in Lifecore Biomedical by 0.8% during the 3rd quarter. Vanguard Group Inc. now owns 1,622,769 shares of the company’s stock worth $11,944,000 after acquiring an additional 12,851 shares during the period. Geode Capital Management LLC grew its stake in shares of Lifecore Biomedical by 0.8% in the fourth quarter. Geode Capital Management LLC now owns 779,642 shares of the company’s stock worth $6,379,000 after purchasing an additional 6,013 shares in the last quarter. Finally, Grizzlyrock Capital LLC bought a new position in shares of Lifecore Biomedical in the second quarter worth $5,964,000. 83.36% of the stock is owned by institutional investors.

Lifecore Biomedical Price Performance

Shares of LFCR opened at $4.06 on Tuesday. The company has a market cap of $152.17 million, a P/E ratio of -4.14 and a beta of 0.62. The stock has a fifty day moving average price of $7.32 and a 200 day moving average price of $7.42. The company has a debt-to-equity ratio of 113.76, a current ratio of 2.80 and a quick ratio of 1.67. Lifecore Biomedical has a 12 month low of $3.98 and a 12 month high of $8.98.

Lifecore Biomedical (NASDAQ:LFCR) last posted its earnings results on Monday, March 16th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.05). Lifecore Biomedical had a negative net margin of 23.08% and a negative return on equity of 1,211.09%. The company had revenue of $35.75 million during the quarter, compared to the consensus estimate of $35.31 million. On average, research analysts forecast that Lifecore Biomedical will post -0.91 earnings per share for the current year.

Lifecore Biomedical Company Profile

Lifecore Biomedical, Inc is a publicly traded specialty biopharmaceutical company headquartered in Chaska, Minnesota. The company focuses on the development, manufacture and commercialization of hyaluronic acid (HA)–based products that address medical and aesthetic needs. Lifecore’s proprietary HA formulations are designed to meet strict regulatory standards for purity, consistency and performance in highly regulated markets.

The company’s product portfolio spans multiple therapeutic areas, including ophthalmology, orthopedics, dermatology and wound care.